🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06210685
Active, not recruiting Not applicable

The ACES Study for Aseptic Pleural Effusion

NCT06210685 · tracked via the Priya Life Science USA tracker
Sponsor
Pleural Dynamics, Inc.
Phase
Not applicable
Started
2024-05-12
Last updated
2025-08-11

Condition(s) studied

Pleural Effusion

Investigational drug(s) / intervention(s)

Automatic Continuous Effusion Shunt implantation

Automatic Continuous Effusion Shunt implantation: The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.

Study summary

The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires.

After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.

Eligibility

Sex
ALL
Min age
21 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Recurrent pleural effusion after thoracentesis for which the physician has determined that a catheter implantation is indicated. 2. Symptoms of PE such as shortness of breath, cough, or chest fullness/chest discomfort based on patient report to physician. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. 4. Patient is willing and able to meet all study requirements, including follow-up visits and receiving study related telephone calls. Exclusion Criteria: 1. Recurrent pleural effusion after thoracentesis for which the physician has determined that a catheter implantation is indicated. 2. Symptoms of PE such as shortness of breath, cough, or chest fullness/chest discomfort based on patient report to physician. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. 4. Patient is willing and able to meet all study requirements, including follow-up visits and receiving study related telephone calls.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Memorial Healthcare System Hollywood Florida
Johns Hopkins School of Medicine Baltimore Maryland
University of North Carolina Pulmonary and Critical Care Medicine Chapel Hill North Carolina
Vanderbilt University Medical Center Nashville Tennessee
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06210685 on ClinicalTrials.gov ↗ ← All trials in the USA